甲基生物的托芬代谢:在CKD-MBD中具有吸引力的治疗标
Guillaume Fernandes1, Stéphane Burtey2, Ward Zadora3
1Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium; Nephrology and Renal Transplantation Research Group, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
慢性病-矿物质和骨疾病 (CKD-MBD) 需要超越传统治疗的新策略. 新兴研究强调了FGF23-α-Klotho轴和酸盐代谢作为CKD-MBD新疗法机会的关键因素.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
背景情况:
- 慢性病-矿物质和骨疾病 (CKD-MBD) 仍然是一个重大的临床挑战.
- 目前针对高酸盐血症,维生素D和二次性甲状腺功能障碍症的治疗方法存在局限性.
- 建议向整体方法转变范式,超越传统的甲状腺激素--酸盐重点.
研究的目的:
- 审查FGF23-α-Klotho轴和CKD-MBD中托失代谢的新兴作用.
- 探索用于管理CKD-MBD的新型治疗点.
- 将最近的见解整合到对CKD-MBD病变的更全面的理解中.
主要方法:
- 最近文献和会议记录的回顾 (2023年马德里KDIGO争议会议).
- 分析FGF23-α-Klotho轴在矿物代谢中的作用.
- 调查托代谢失调和尿素毒素对CKD-MBD的影响.
主要成果:
- FGF23-α-Klotho轴被确定为矿物代谢的关键调节器和潜在的治疗标.
- 甲的代谢失调,包括性毒素如硫酸,氨酸和氨酸的积累,与CKD相关的骨质疏松症和心血管疾病有关.
- 这些代谢物可能通过直接的细胞效应或酸受体 (AhR) 激活来产生毒性.
结论:
- 对于CKD-MBD,需要采用整体方法,包括新的途径.
- FGF23-α-Klotho轴呈现了一个有前途的新疗法途径.
- 了解托芬代谢障碍为治疗CKD-MBD中心血管和骨并发症提供了新的策略.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
09:31PCR Mutagenesis, Cloning, Expression, Fast Protein Purification Protocols and Crystallization of the Wild Type and Mutant Forms of Tryptophan Synthase
Published on: September 26, 2020
相关概念视频
Chronic Kidney Disease III: Interprofessional Care
Therapeutic Drug Monitoring: Affecting Factors
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Factors Affecting Drug Biotransformation: Biological
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
